Comorbidities, multimorbidity and COVID-19
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …
earliest days of the pandemic. But establishing causality and determining underlying …
A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
COVID-19 therapeutics: Challenges and directions for the future
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022 - thelancet.com
Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
[HTML][HTML] Using genetic association data to guide drug discovery and development: review of methods and applications
Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …
expensive and slow to obtain. In contrast, evidence from conventional observational …
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells
The molecular mechanisms governing orderly shutdown and retraction of CD4+ type 1
helper T (TH1) cell responses remain poorly understood. Here we show that complement …
helper T (TH1) cell responses remain poorly understood. Here we show that complement …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …